The optimal time to inject bone mesenchymal stem cells for fracture healing in a murine model

Stem Cell Res Ther. 2018 Oct 25;9(1):272. doi: 10.1186/s13287-018-1034-7.

Abstract

Background: Bone marrow is an important source of stem cells, which can promote bone fracture healing.

Methods: We investigated the optimal time to inject bone marrow mesenchymal stem cells (BMSCs) in a C57 murine unilateral, transverse, femur fracture model. BMSCs transfected with red fluorescent protein (RFP-BMSCs) were injected via the tail vein on day 1, 7, or 14 post-fracture. AMD3100 (inhibitor of stromal cell-derived factor 1 [SDF-1]) was also injected before RFP-BMSCs in one group for comparison; a control group received saline injections. RFP-BMSC migration and fracture healing were evaluated by in vivo fluorescence assay. Micro-CT was performed and mechanical testing and histological analysis. Chemokine levels were evaluated by quantitative real-time PCR and western blotting.

Results: Following injection on day 7 post-fracture, RFP-BMSCs more frequently homed to the fracture site and remained for a longer duration. Bone volume and bone mineral density were increased when BMSCs were injected on day 7 post-fracture (P < 0.05). The mechanical properties of fractured femurs were improved following day-7 BMSC injection. Histology confirmed that BMSC injection improved the formation of new bones.

Conclusions: Chemokines that induce BMSC migration were highly expressed, and protein levels of osteogenesis-related factors were increased. Seven days after fracture may be the optimal time for injection of BMSCs to promote fracture healing. Additionally, the SDF-1/CXCR4 pathway may play an important role in fracture healing following BMSC injection.

Keywords: Fracture healing; Homing; Mesenchymal stem cells; Migration; Stromal cell-derived factor 1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzylamines
  • Bone Density
  • Bone Regeneration / genetics
  • Cell Engineering
  • Chemokine CXCL12 / antagonists & inhibitors
  • Chemokine CXCL12 / genetics*
  • Chemokine CXCL12 / metabolism
  • Cyclams
  • Disease Models, Animal
  • Femoral Fractures / diagnostic imaging
  • Femoral Fractures / genetics
  • Femoral Fractures / pathology
  • Femoral Fractures / therapy*
  • Femur / diagnostic imaging
  • Femur / injuries
  • Femur / metabolism
  • Fracture Healing / genetics*
  • Gene Expression
  • Heterocyclic Compounds / pharmacology
  • Luminescent Proteins / genetics
  • Luminescent Proteins / metabolism
  • Male
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / drug effects
  • Mesenchymal Stem Cells / metabolism*
  • Mice
  • Mice, Inbred C57BL
  • Osteogenesis / genetics
  • Receptors, CXCR4 / genetics*
  • Receptors, CXCR4 / metabolism
  • Red Fluorescent Protein
  • Signal Transduction
  • Time Factors
  • Transfection
  • X-Ray Microtomography

Substances

  • Benzylamines
  • CXCR4 protein, mouse
  • Chemokine CXCL12
  • Cxcl12 protein, mouse
  • Cyclams
  • Heterocyclic Compounds
  • Luminescent Proteins
  • Receptors, CXCR4
  • plerixafor